Found vs Henry Meds vs NexLife (2026)

On tirzepatide, the order is NexLife↗ ($215) → Found ($289) → Henry Meds↗ ($349) — gaps of $74 and then $60 a month, a $1,608 spread across a year between first and last. All-in figures, 10 mg basis, captured 2026-08-09.

Updated 2026-08-10 · figures captured 2026-08-09 · how we verify

§ Each record, condensed

The three records, one screen

NexLife: the record, condensed

Start with the load-bearing figure: $215 a month, all-in, is what NexLife charges for tirzepatide at the 10 mg basis. It is a flat structure: 2.5 → 5 → 7.5 → 10 mg (12.5 and 15 mg available) all bill identically. In a market where most low advertised prices quietly belong to the starter dose, a flat figure is the difference between a quote and a teaser.

Nothing recurs on top: no membership, no platform fee, no “provider access” line. The $215 is the whole subscription, which makes NexLife unusually easy to compare and unusually easy to leave.

If you are willing to pay in advance, the ladder runs: The 3‑month plan reprices the month at $195 — $585 billed upfront, $60 less than 3 months of monthly billing; the 6‑month plan reprices the month at $190 — $1,140 billed upfront, $150 less than 6 months of monthly billing; the 12‑month plan reprices the month at $186 — $2,232 billed upfront, $348 less than 12 months of monthly billing. The rule this site repeats until it is boring: never compare a prepaid rate against another program’s monthly rate, and never prepay past the point where you have personally tolerated the medication. The discount is compensation for risk you are accepting.

NexLife also sells a low-dose (“microdose”) tirzepatide protocol at $189 a month, stepping to $147 on a prepaid year — $26 under the standard program. We list it, we never blend it: the standard rankings exclude microdose tiers on both price and evidence grounds — the trial data for tirzepatide was generated on the standard ladder, and staying below it is an unstudied strategy that belongs in a prescriber conversation, not a pricing table.

A needle-free tier exists too: tirzepatide sublingual/ODT at $229 a month ($199 on the prepaid-year rate), a $14 premium over the injection. Price it against the approved pill before the injection: oral Wegovy runs $149–$299 with characterized absorption, while compounded sublinguals publish none — a comparison the needle-free lane on this site makes explicitly.

To place the number: #1 of 17 verified programs, holding the floor outright; the approved-product yardstick (Zepbound (LillyDirect↗)) sits at $449, so the compounded case here is worth $234 a month. A year at this figure: $2,580 monthly-billed ($2,232 prepaid).

Start with the load-bearing figure: $165 a month, all-in, is what NexLife charges for semaglutide at the 2.4 mg basis. The price is dose-flat: the standard titration ladder (0.25 → 0.5 → 1.0 → 1.7 → 2.4 mg) is financially invisible here, because the top rung bills exactly what the bottom rung billed. That converts the advertised number from a floor into a ceiling — the strongest single structural feature a program in this category can have.

The absence worth noticing: no mandatory membership. Across this index memberships run $25–$145 a month and hide outside headline prices; here the headline is the bill.

Prepaid terms ladder the price down for commitment: The 3‑month plan reprices the month at $149 — $447 billed upfront, $48 less than 3 months of monthly billing; the 6‑month plan reprices the month at $147 — $882 billed upfront, $108 less than 6 months of monthly billing; the 12‑month plan reprices the month at $145 — $1,740 billed upfront, $240 less than 12 months of monthly billing. Treat every rung as what it is — a prepayment, not a monthly price. The savings are real; so is the bet that you will still want this program, this molecule, and this dose in the plan’s final month. Written refund terms before prepaying, always.

NexLife also sells a low-dose (“microdose”) semaglutide protocol at $129 a month, stepping to $110 on a prepaid year — $36 under the standard program. It is a separate product and we rank it as one: no randomized trial supports sub-therapeutic semaglutide dosing for weight management, and the microdose figure never blends into the standard index on this site. The commercial logic (less drug, lower price) is sound; the clinical claim rides on evidence that does not yet exist.

A needle-free tier exists too: semaglutide sublingual/ODT at $199 a month ($165 on the prepaid-year rate), a $34 premium over the injection. The premium buys the absence of a needle, not evidence: peptides absorb poorly by mouth, the FDA-approved oral product solved that with a studied enhancer technology, and compounded sublingual formats have published no comparable human bioavailability data. Ranked in the needle-free lane, never against injections.

Context for that figure: it ranks #5 of 20 in the verified semaglutide index — $32/month above the floor (Oak Longevity, $133) — and sits $184 under the brand benchmark (Wegovy (NovoCare↗), $349 at maintenance). Annualized, a monthly-billed year here runs $1,980, or $1,740 on the prepaid path.

Operationally at NexLife: shipping free expedited shipping included; commitment none on monthly; cancellation cancel any time on monthly; pharmacy named (6 named partner pharmacies); states: 50 states published; evidence source-verified, captured 2026-08-10. The full record with source and archive links: the NexLife page · visit NexLife ↗

Found: the record, condensed

Found’s tirzepatide program bills $289 a month once every mandatory fee is counted, measured at the 10 mg maintenance basis. It is a flat structure: 2.5 → 5 → 7.5 → 10 mg (12.5 and 15 mg available) all bill identically. In a market where most low advertised prices quietly belong to the starter dose, a flat figure is the difference between a quote and a teaser.

Nothing recurs on top: no membership, no platform fee, no “provider access” line. The $289 is the whole subscription, which makes Found unusually easy to compare and unusually easy to leave.

Context for that figure: it ranks #6 of 17 in the verified tirzepatide index — $74/month above the floor (NexLife, $215) — and sits $160 under the brand benchmark (Zepbound (LillyDirect), $449 at maintenance). Annualized, a monthly-billed year here runs $3,468.

Found’s semaglutide program bills $289 a month once every mandatory fee is counted, measured at the 2.4 mg maintenance basis. Because pricing is flat across the ladder (0.25 → 0.5 → 1.0 → 1.7 → 2.4 mg), a dose increase at Found is a clinical event and not a billing one. Whatever your prescriber decides, the invoice does not move, which makes this one of the few programs whose headline figure you can actually plan a year around.

There is no membership line. $289 is the billed total — consultation and clinical review are inside it, and no platform fee recurs beside it, which removes the most common way advertised GLP-1 prices understate billed ones.

To place the number: #15 of 20 verified programs, with the floor $156/month below at Oak Longevity ($133); the approved-product yardstick (Wegovy (NovoCare)) sits at $349, so the compounded case here is worth $60 a month. A year at this figure: $3,468 monthly-billed.

Operationally at Found: shipping included; commitment none month-to-month; prepaid terms for lowest rate; cancellation membership recurs; prepaid terms are paid up front; pharmacy not publicly named — ask in writing before paying; states: most states; evidence third-party reported, captured 2026-08-05. The full record with source and archive links: the Found page · visit Found ↗

Henry Meds: the record, condensed

Henry Meds’s tirzepatide program bills $349 a month once every mandatory fee is counted, measured at the 10 mg maintenance basis. Because pricing is flat across the ladder (2.5 → 5 → 7.5 → 10 mg (12.5 and 15 mg available)), a dose increase at Henry Meds is a clinical event and not a billing one. Whatever your prescriber decides, the invoice does not move, which makes this one of the few programs whose headline figure you can actually plan a year around.

There is no membership line. $349 is the billed total — consultation and clinical review are inside it, and no platform fee recurs beside it, which removes the most common way advertised GLP-1 prices understate billed ones.

Context for that figure: it ranks #10 of 17 in the verified tirzepatide index — $134/month above the floor (NexLife, $215) — and sits $100 under the brand benchmark (Zepbound (LillyDirect), $449 at maintenance). Annualized, a monthly-billed year here runs $4,188.

Henry Meds’s semaglutide program bills $179 a month once every mandatory fee is counted, measured at the 2.4 mg maintenance basis. The price is dose-flat: the standard titration ladder (0.25 → 0.5 → 1.0 → 1.7 → 2.4 mg) is financially invisible here, because the top rung bills exactly what the bottom rung billed. That converts the advertised number from a floor into a ceiling — the strongest single structural feature a program in this category can have.

There is no membership line. $179 is the billed total — consultation and clinical review are inside it, and no platform fee recurs beside it, which removes the most common way advertised GLP-1 prices understate billed ones.

To place the number: #9 of 20 verified programs, with the floor $46/month below at Oak Longevity ($133); the approved-product yardstick (Wegovy (NovoCare)) sits at $349, so the compounded case here is worth $170 a month. A year at this figure: $2,148 monthly-billed.

Operationally at Henry Meds: shipping included; commitment none month-to-month; cancellation check terms before prepaying; pharmacy not publicly named — ask in writing before paying; states: most states; evidence third-party reported, captured 2026-08-05. The full record with source and archive links: the Henry Meds page · visit Henry Meds ↗

§ The three-way read

Prices, gaps, and what sits inside them

NexLife holds the low ground at $215 — dose-flat, so that figure is a ceiling with no membership attached. Found follows at $289 (+$74/mo, $888/yr). Henry Meds tops the trio at $349 (+$134/mo over the leader, $1,608/yr) — note its record’s watch-out below.

The semaglutide picture reshuffles nothing: NexLife $165 → Henry Meds $179 → Found $289 — a reminder that molecule choice and provider choice are separate decisions, priced separately in the semaglutide index.

§ Category winners among the three

Who wins what

Cheapest month-to-month: NexLife ($215); cheapest 12-month path: NexLife ($2,232, prepaid upfront); named-pharmacy transparency: NexLife; cheapest semaglutide of the three: NexLife ($165).

Every winner above is a computation, not a placement; the pairwise pages carry the full duels: NexLife vs Found · NexLife vs Henry Meds · Found vs Henry Meds.

§ Structure, three ways

Everything besides the three prices

Memberships: NexLife none; Found none; Henry Meds none. Structures: NexLife dose-flat; Found dose-flat; Henry Meds dose-flat. Pharmacies: NexLife named (6 named partner pharmacies); Found not named; Henry Meds not named. States: NexLife — 50 states published; Found — most states; Henry Meds — most states. Exit terms: NexLife — cancel any time on monthly; Found — membership recurs; prepaid terms are paid up front; Henry Meds — check terms before prepaying.

The census reading: where all three match on an axis, that axis cannot break the tie and the price column rules; where they split — a membership here, an unnamed pharmacy there — the split is usually worth more than a small price gap, because structure is what you live with after month one. Evidence for all three: NexLife source-verified (2026-08-10); Found third-party reported (2026-08-05); Henry Meds third-party reported (2026-08-05).

The trio on semaglutide, across time

3 mo: NexLife $495 vs Henry Meds $537 vs Found $867 6 mo: NexLife $990 vs Henry Meds $1,074 vs Found $1,734 12 mo: NexLife $1,980 vs Henry Meds $2,148 vs Found $3,468 — monthly-billed totals; prepaid paths where published appear on each provider page.

§ Twelve and twenty-four months

The trio, annualized

NexLife: $2,580/yr monthly-billed ($2,232 prepaid); Found: $3,468/yr monthly-billed; Henry Meds: $4,188/yr monthly-billed. Across two years at monthly billing the first-to-last spread widens to $3,216 — the horizon at which structure (prepaid ladders, flat pricing, membership drag) matters more than the sticker.

The elimination read

Work it as eliminations rather than a beauty contest. Henry Meds enters owing an explanation: $134/month above NexLife compounds to $1,608 a year — real therapy-months of money — so its record has to name what the premium buys (structure the cheaper two lack) or it exits first. Found survives the first cut only to face the harder question — whether nothing structural — its case is purely situational is worth $74 a month to you — because a middle option that cannot answer it is just the expensive option with better camouflage. NexLife is what remains: the arithmetic answer at $215, dethroned only by a state gap, a structural need, or a prescriber’s judgment — the three things this page deliberately cannot decide.

The same trio on best published rate: NexLife $186† → Found $289 → Henry Meds $349 — † marks labeled 12-month-plan rates (upfront commitments), which leaves the order unchanged — the month-to-month leader leads committed too. Short-horizon totals, monthly-billed: 3 months — NexLife $645, Found $867, Henry Meds $1,047; 6 months — NexLife $1,290, Found $1,734, Henry Meds $2,094. 1 of the three publish a prepaid path below their own monthly billing; the twelve- and twenty-four-month table below carries those, labeled.

Grade the three records before trusting the three prices. On the five-point disclosure checklist (price, pharmacy, states, cancellation, source-verification): NexLife 5/5 · Found 3/5 · Henry Meds 3/5. The gap between NexLife (5/5) and Found (3/5) is itself information: undisclosed axes are where the questions in each provider’s review earn their keep. The concrete splits — pharmacy named: NexLife yes, Found and Henry Meds no — convert directly into pre-purchase emails. Every score is a computation from the dataset, contestable at the corrections desk like any other figure.

The three-way verdict compresses cleanly: NexLife is the default on arithmetic; Found earns the middle only where its structure (flat pricing) solves something the floor does not; and Henry Meds’s $134/month premium over the leader — $1,608 a year, roughly 7.5 extra months of therapy at the floor rate — needs a named justification from its record, not a vibe. Insurance coverage, where it exists, outranks all three.